Scott Brun
About Scott Brun
Scott Brun, M.D., age 57, has served on Cabaletta Bio’s board since June 2021 and is a Class I director with a term expiring at the 2026 annual meeting; the board has determined he is independent under Nasdaq and SEC rules . He is President of Gold Mast Consulting (founded in 2019), a Venture Partner at Abingworth LLP, and Senior Medical Advisor to Launch Therapeutics . His prior roles include Corporate Vice President of Scientific Affairs and Head of AbbVie Ventures (2016–2019) and Corporate Vice President & Head of Pharmaceutical Development at AbbVie (2013–2016), following 15 years in R&D leadership at Abbott Laboratories; he holds a B.S. in Biochemistry (University of Illinois), an M.D. (Johns Hopkins), and completed an ophthalmology residency at Massachusetts Eye and Ear, Harvard Medical School .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| AbbVie, Inc. | Corporate VP, Scientific Affairs; Head of AbbVie Ventures | 2016–2019 | Led investments within R&D therapeutic areas and platform technologies |
| AbbVie, Inc. | Corporate VP & Head of Pharmaceutical Development | 2013–2016 | Oversaw early/late-stage clinical pipeline and marketed compounds across multiple therapeutic areas |
| Abbott Laboratories | R&D leadership roles | ~15 years prior to AbbVie spin | Increasing responsibility in drug development within R&D |
External Roles
| Organization | Role | Public/Private | Tenure/Notes |
|---|---|---|---|
| Gold Mast Consulting, LLC | President | Private | Founded 2019 |
| Abingworth LLP | Venture Partner | Private | Current role |
| Launch Therapeutics | Senior Medical Advisor | Private | Current role |
| Jasper Therapeutics, Inc. (Nasdaq: JSPR) | Director | Public | Biotechnology company; board service disclosed |
| Forte Biosciences, Inc. (Nasdaq: FBRX) | Director | Public | Preclinical-stage; autoimmune focus; board service disclosed |
| Axial Biotherapeutics, Inc. | Director | Private | Clinical-stage; board service disclosed |
| Trishula Therapeutics, Inc. | Director | Private | Clinical-stage; board service disclosed |
| Horizon Therapeutics plc (Nasdaq: HZNP) | Senior Advisor (Business Dev.) | Public | 2020–2023 (prior role) |
Board Governance
- Committee assignments: Audit Committee member; Nominating & Corporate Governance Committee chair; Science & Technology Committee member .
- Committee meeting cadence (FY2024): Audit (6 meetings), Nominating & Corporate Governance (2), Science & Technology (4) .
- Board attendance: The full board met 9 times in 2024; each director attended 90%+ of combined board and committee meetings. Five of six directors attended the 2024 annual meeting .
- Independence: Board determined all non-employee directors, including Dr. Brun, are independent per Nasdaq/SEC (CEO excluded) .
- Audit oversight: Audit Committee monitors financial reporting integrity, pre-approves auditor services, reviews related person transactions, and oversees risk/cybersecurity .
Fixed Compensation
| Component | 2024 Policy Member Annual Retainer ($) | 2024 Policy Chair Retainer ($) | 2025 Policy Member Annual Retainer ($) | 2025 Policy Chair Retainer ($) |
|---|---|---|---|---|
| Board of Directors | 40,000 | — | 40,000 | — |
| Audit Committee | 7,500 | 15,000 | 10,000 | 20,000 |
| Compensation Committee | 5,500 | 11,000 | 6,250 | 12,500 |
| Nominating & Corporate Governance Committee | 5,000 | 10,000 | 5,000 | 10,000 |
| Science & Technology Committee | 7,500 | 15,000 | 7,500 | 15,000 |
| Director (2024) | Fees Earned or Paid in Cash ($) | All Other Compensation ($) | Total ($) |
|---|---|---|---|
| Scott Brun, M.D. | 65,000 | — | 246,810 |
- Reimbursement: Reasonable out-of-pocket expenses for board/committee meetings .
- Compensation consultant: Radford serves as independent advisor to the Compensation Committee, including non-employee director pay; independence affirmed .
Performance Compensation
| Equity Award Parameter | Value/Terms |
|---|---|
| 2024 Option Award (Grant-date fair value) | $181,810 (FASB ASC 718) |
| Initial Director Option Grant | 44,000 options; vest in equal quarterly installments over 3 years, subject to continued service |
| Annual Director Option Grant | 22,000 options at each annual meeting; vest in full by first anniversary or next annual meeting; vesting ceases upon resignation unless board determines continuation warranted |
| Performance Metrics | None disclosed for director equity; awards are time-based options (no revenue/EBITDA/TSR metrics) |
No director meeting fees are disclosed; equity awards are option-based rather than RSUs/PSUs, reinforcing alignment with shareholder outcomes through option value realization .
Other Directorships & Interlocks
| Company | Role | Potential Interlock/Considerations |
|---|---|---|
| Jasper Therapeutics, Inc. (Nasdaq: JSPR) | Director | Public biotech; no related-party transactions with Cabaletta since 1/1/2023 |
| Forte Biosciences, Inc. (Nasdaq: FBRX) | Director | Public biotech; no related-party transactions with Cabaletta since 1/1/2023 |
| Axial Biotherapeutics, Inc. | Director | Private clinical-stage; no related-party transactions disclosed |
| Trishula Therapeutics, Inc. | Director | Private clinical-stage; no related-party transactions disclosed |
- Related person policy: Audit Committee must approve related person transactions >$120,000; none reported since 1/1/2023 involving directors/5% holders .
Expertise & Qualifications
- Scientific and clinical development leadership across autoimmune, neurology, renal, oncology, infectious disease, and women’s/men’s health; extensive portfolio management and venture investing experience .
- Education: B.S. Biochemistry (University of Illinois); M.D. (Johns Hopkins); ophthalmology residency at Massachusetts Eye and Ear (Harvard Medical School) .
Equity Ownership
| Item | Value |
|---|---|
| Shares Beneficially Owned (as of 4/28/2025) | 110,000; 0.22% of outstanding shares (50,743,101 total) |
| Options/Unvested Equity (as of 12/31/2024) | Options outstanding: 110,000; Unvested shares: 22,000 |
| Pledging/Hedging Policy | Prohibits short sales, derivative transactions, and pledging/margin use without Audit Committee approval; generally prohibits derivative/hedging |
Audit Committee reviews and approves related person transactions to manage conflicts; insider trading policies include trading pre-clearance and Rule 10b5-1 plan limitations .
Governance Assessment
- Board effectiveness: Active committee leadership (chair of Nominating & Corporate Governance) and service on Audit and Science & Technology; strong attendance (90%+); board met nine times in 2024 .
- Independence & conflicts: Independence affirmed; no related-party transactions >$120k reported; Audit Committee oversight of related person transactions mitigates conflict risk .
- Compensation alignment: Director pay mix emphasizes equity via options; 2025 committee retainers modestly increased (e.g., Audit member $10k from $7.5k), with continued annual option grants (22,000) to align with shareholders .
- Risk controls: Robust insider trading/hedging/pledging prohibitions; clawback policy adopted for executive officers (Dodd-Frank/Nasdaq compliance) .
- RED FLAGS: None disclosed—independence affirmed; high attendance; no related party transactions; no hedging/pledging allowed .